KMT2A and leukemia: The most central nodes of the KMT2A-AFF1 GRN (degree centrality > 500, 8/3850 nodes) are constitutively active across ALL and AML patient subnetworks (Fig. 2B) and are bound by KMT2A-AFF1 in the ALL patient ChIP-seq samples, indicating that they are commonly up-regulated by KMT2A-AFF1 in leukemia (Supplemental Fig. S3B).